Maybe. Makes sense, I'm just not sure they can afford us. They have a market cap of 105 billion. If they were to offer say $30/share it would be $21 billion.

Possibly a cash plus stock type offer.

I still think the issue is that we value our drug higher than they do. I would expect buyout offers to be in the $10-15/share range, and I don't believe shareholders would approve that.

Similarly, I don't think we get an offer north of $25.